IVD Antibody Development Services for PCA3 Marker

1. IVD Antibody Development Services for PCA3 Marker Creative Biolabs is a world leader in the field of in vitro diagnostics (IVD) antibody development. With our extensive experience and advanced platform, we provide a range of IVD antibody development services against PCA3 marker for the diagnosis of prostate cancer. PCA3 Markers research has been the focus of many laboratories across the world. Within the last decade, due to a significant advance in genetics and cell biology, new emerging molecular markers have been widely investigated. Their appearance has been the natural consequence of recently described genetic changes in PCa including gene fusions and messenger RNA (mRNA) alterations. Several worth reporting biomarkers have been identified and a great amount of work has been done so far in an effort to develop new assays based on the recent findings. The only marker which has been introduced into clinical diagnosis remains Prostate Cancer Antigen 3 (PCA3). PCA3 as Marker of Prostate Cancer PCA3 is the most specific clinically available prostate malignancy marker described so far: PCA3 RNA expression is restricted to prostate, i.e., it is not expressed in any other normal human tissue nor in any other tumor. The presence of PCA3 RNA was firstly reported by Bussemakers et al. in 1999. Since its discovery, the structure of PCA3 has been widely investigated, and most recently four new transcription start sites as well as two additional exon sequences and four additional polyadenylation sites have been described. The

2. PCA3 RNA is highly overexpressed in 95% of tumors compared to normal or benign hyperplastic prostate tissue. PCA3 Antibodies for Diagnostics of Prostate Cancer Since cancer cells with high levels of PCA3 are shed from the prostate into the urine, the level of PCA3 RNA can be detected not only in prostate tissue specimens but also in urine and urinary sediments after prostate massage. Unlike PSA tests, PCA3 based diagnosis is independent of prostate volume, the number of previous biopsies, and the age of patients. Most importantly, this diagnosis is not affected by the main causes of non-cancerous PSA elevations, such as benign prostatic hyperplasia (BPH) and prostatitis. Therefore, PCA3 assays are more specific than serum PSA and are very useful for detecting the presence of PCa in men who are frequently observed for other causes of elevated PSA, including glandular inflammation and their increased size. The expression of PCA3 is unaffected by the pharmacotherapy of the gland including the application of type I and II 5-α reductase inhibitors. In addition, the PCA3 test allows detection of pre-cancerous lesions known in PCa as high- grade prostatic intraepithelial neoplasia (HGPIN). Other uses that are being studied for PCA3 include its correlation with adverse tumor features such as tumor volume, grading (Gleason score) and extracapsular extension. Creative Biolabs offers anti-PCA3 antibody development services for use of in vitro diagnostic (IVD) of prostate cancer. Such antibody can be used for differential diagnosis of prostate cancer with high sensitivity. Our advantage is not only our antibodies but also our development service! We guarantee our customers quality products at a reasonable price. Creative Biolabs has focused on IVD antibody discovery for years. We have experts who are able to develop high-affinity IVD antibodies against varies of markers. We are therefore confident in offering the most suitable service and finest results for our customers all over the world. If you are interested in our IVD antibody discovery services, please contact us for more details. Related Services: IVD Antibody Development Services for Survivin Marker IVD Antibody Development Services for PSA Marker IVD Services for miR-141 Marker IVD Assay Services for miR-375 Marker